CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group Limited has announced that their Roxadustat Capsules, the first generic drug of its kind in China, received drug registration approval for treating anemia associated with chronic kidney disease. The product, which is a hypoxia-inducible factor-prolyl hydroxylase inhibitor, offers a novel treatment mechanism and has been highly recommended in Chinese clinical guidelines. This approval is expected to enhance the company’s blood and hemopoietic system product portfolio, providing new options for patients.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
